David D. Chang - 16 Mar 2026 Form 4 Insider Report for Allogene Therapeutics, Inc. (ALLO)

Role
President and CEO, Director
Signature
/s/Earl Douglas, Attorney-in-Fact
Issuer symbol
ALLO
Transactions as of
16 Mar 2026
Net transactions value
-$117,975
Form type
4
Filing time
18 Mar 2026, 16:05:48 UTC
Previous filing
04 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Chang David D President and CEO, Director 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO /s/Earl Douglas, Attorney-in-Fact 18 Mar 2026 0001611024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALLO Common Stock Sale $117,975 -47,763 -0.92% $2.47 5,150,599 16 Mar 2026 Direct F1, F2
holding ALLO Common Stock 856,044 16 Mar 2026 See footnote F3
holding ALLO Common Stock 856,044 16 Mar 2026 See footnote F4
holding ALLO Common Stock 1,201,108 16 Mar 2026 See footnote F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1. Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F2 3. Includes 12,500 shares of the Issuer's common stock acquired by the reporting person on March 15, 2026 pursuant to an employee stock purchase program.
F3 Securities held in the name of the RTC 2019 Trust dated October 1, 2019.
F4 Securities held in the name of the JEC 2019 Trust dated October 1, 2019.
F5 Securities held in the name of the Chang 2006 Family Trust